Patients with any grade neutropenia in the beginning of CDK4/6i treatment: C1D1, C1D14, or C2D1 had a higher risk of CDK4/6i dose reduction (p = 0.006; p < 0.0001; p < 0.0001, respectively). The gene discussed is CDK4; the disease is Decreased total neutrophil count.